Duke University

Harvard College

University of Florida Research Foundation Inc

Emory University

The United States Government As Represented by the Department of Veterans Affairs

Editas Medicine, Inc.

Bryan R Cullen

Yan Zeng

Raymond F Schinazi

David A Bumcrot

Ari E Friedland

David Clair Bloom

Donald M Coen

David M Knipe

Penrose O'Donnell

Wade S Blair

Hal P Bogerd

Dane M Phelan

Anand Kornepati

Matthew E Kennedy

Adam Mefferd

Jennifer Lin Umbach

Martha F Kramer

E Matthew Kennedy

Igor Jurak

Yang Zeng

Genome editing systems and genetic constructs that target a herpes simplex virus (HSV) viral gene, where the systems comprise one Cas9 molecule, and a gRNA molecule, compositions and cells comprising such genome editing systems and genetic constructs as well as methods for using the genome editing systems, genetic constructs, compositions and cells for genome engineering, and for preventing, treating or reducing HSV infection.

CRISPR/cas-related methods and compositions for treating herpes simplex virus

The subject invention pertains to materials and methods for the treatment of latent viral infections.

Materials and methods for the treatment of latent viral infection

Provided herein are recombinant constructs, vectors and expression cassettes including a first promoter which is suitably a tRNA promoter operably connected to a first polynucleotide encoding a first single guide RNA and a second promoter operably connected to a second polynucleotide encoding a Cas9 polypeptide. The first single guide RNA includes a first portion complementary to a strand of a target sequence of a DNA virus and a second portion capable of interacting with the Cas9 polypeptide. Also provided are codon optimizedderived Cas9 polynucleotides and polypeptides with nuclear localization signals and optionally an epitope tag. Also provided are constructs for production of sgRNAs including a tRNA. Methods of inhibiting viral replication, inhibiting expression of a target sequence from a virus or treating a viral infection or viral induced cancer using the compositions are also provided.

Compositions for the inactivation of virus replication and methods of making and using the same

The present invention relates, in general, to gene expression and, in particular, to a method of inhibiting the expression of a target gene and to constructs suitable for use in such a method.

Method of regulating gene expression

The present invention relates, in general, to micro RN As and, in particular, to viral microRNAs expressed by Herpes Simplex Vims 1 (HSV-1) or Herpes Simplex Virus 2 (HSV-2), to agents that inhibit such microRNAs and to methods of treatment based on the use of such agents.

Viral microRNA

The present invention relates, in general to an assay method, and, in particular, to an in vivo method of assaying the interaction of RNA with proteins. The invention relates to a kit suitable for use in connection with such method.

Method of assaying for RNA: protein interactions

Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication

Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-1 and corresponding mutated genes, having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II. And in some cases both the Rev and the Rex function and are, active in more than one viral species. Such transdominant viral mutants are useful as anti-viral agents to, for example of these transdominant inhibitors may be used in such therapeutic approaches as intracellular immunization in order to protect cells against the deleterious effects of viral, e.g. HIV-1, infection.

Mutant Rev transdominant repressors of HIV replication

Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-1 and corresponding mutated genes, having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II and, in some cases, both the Rev and the Rex function and are, therefore, active in more than one viral species. Such transdominant viral mutants are useful as anti-viral agents to, for example, protect cells against the deleterious effects of viral, e.g. HIV-1, infection.

Mutant rev genes encoding transdominant repressors of HIV replication

Growing community of inventors

Durham, NC, United States of America

Bryan R Cullen